SCHEMBL9893327

SCHEMBL9893327

CC(C)(C)OC(=O)CN(CC(=O)OC(C)(C)C)C(=O)CCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 4/20 0.39
KDM2A Q9Y2K7 4/20 0.39
EGLN1 Q9GZT9 3/20 0.38
KDM6B O15054 2/20 0.38
KDM5C P41229 2/20 0.38
LMNA P02545 2/20 0.37
SLC15A2 Q16348 1/20 0.37
HDAC6 Q9UBN7 3/20 0.33
TSHR P16473 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALKBH5 Q6P6C2 1/20 0.33
SUCNR1 Q9BXA5 1/20 0.33
USP2 O75604 1/20 0.33
KDM4E B2RXH2 1/20 0.32
KDM4A O75164 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
CASR P41180 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9945620 0.95 PHF8 (0.39) PHF8KDM2AEGLN1KDM6BKDM5C
SCHEMBL13254363 0.85 PHF8 (0.34) PHF8KDM2AEGLN1KDM6BKDM5C
SCHEMBL15706325 0.83 KDM5A (0.40) PHF8KDM5CTSHRTDP1KDM4C
SCHEMBL27322839 0.83 PHF8 (0.35) PHF8KDM2AEGLN1KDM6BKDM5C
SCHEMBL17384424 0.82 CTSL (0.50) LMNATSHRHDAC1HDAC2POLB
SCHEMBL17384567 0.80 CYP3A4 (0.47) PHF8KDM2AHDAC6HDAC1HDAC2
SCHEMBL18116039 0.79 CA14 (0.41) PHF8KDM2AEGLN1KDM6BKDM5C
SCHEMBL1742306 0.79 AKT1 (0.38) TSHRTDP1CASRALDH1A1
SCHEMBL782399 0.79 MEN1 (0.31) TSHRTDP1CASR
SCHEMBL6534709 0.79 HDAC6 (0.33) HDAC6HDAC1HDAC2TDP1CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024016071-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2024-01-25 WO disclosed
US-8901072-B2 Glycopeptide and lipoglycopeptide antibiotics with improved solubility THE MEDICINES COMPANY (US) 2014-12-02 US disclosed
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY THE MEDICINES COMPANY (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY NGLY1, LGALS3BP, GYPA PHF8 4449/4885KDM2A 4157/4885EGLN1 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.